NeuVax

Galena Biopharma’s Breast Cancer Vaccine Sprouts More Red Flags

May 29th, 2012 |

More red flags have been found staked into Galena Biopharma’s(GALE _) breast cancer vaccine NeuVax.

Updated, 60-month follow-up results from a Neuvax phase II study scheduled for presentation next month at the American Society of Clinical Oncology (ASCO) annual meeting don’t appear to be new or consistent with previously reported data.

Galena presented the same 60-month NeuVax analysis last December at the San Antonio Breast Cancer Symposium except the numbers are different.

Asked to explain the discrepancies between NeuVax data from last December and “new” NeuVax data coming next month at ASCO, Galena spokeswoman Remi Bernarda told me, “I don’t have answers from the company at this time.”

Let’s dig into the controversy:

The NeuVax research abstract submitted for next month’s ASCO meeting — posted on May 16 — describes a subset of 53 patients from the phase II trial (187 patients were enrolled overall) who were “optimally dosed” with booster shots every six months following an initial set of six monthly injections. The booster shots were designed to enhance or prolong the immunotherapeutic effect of NeuVax.

Read the rest here.